MedTrace Logo

STUDY OF SURVIVAL AND FUNCTIONALITY IN CRYOPRESERVED PLATELETS

NCT04754841 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2021-08-03

No results posted yet for this study

Summary

Platelets correspond to one of the most widely used blood components in transfusion medicine, given their importance in the prevention of bleeding disorders in patients with multifactorial thrombocytopenia and non-immunological etiology, as well as in the management of traumatic or blood-related bleeding. surgical treatments. Given its wide margin of use and the constant demand for it for use within the different management schemes and procedures associated with the medical act, it is the objective of both hemotherapy services and blood banks and blood products to have availability component constant to meet such requirements. The main problem of this resource is its short useful life (5 to 7 days) which limits its availability, especially in the Latin American context where the production of blood components as well as the resources allocated for this purpose by state entities to blood banks are generally limited. Cryopreservation at -80 ° C using Dimethylsulfoxide as a preservative solution is a technique used since the 1950s to prolong platelet survival, the improvement of which has been remarkable in recent years, thus constituting an alternative for the resolution of this problem.

Conditions

  • Platelet Cryopreservation
  • Platelet Survival

Interventions

OTHER

platelet cryopreservation

The cryopreservation of platelets will be carried out using as alternatives of cryopreservative solution: 5% dimethylsulfoxide alone (solution 1) or combined with 5% dextrose 160 mg (solution 2) or with 2% albumin (solution 3) and then be frozen at -80 ° C

Sponsors & Collaborators

  • HOSPITAL BRITANICO DE BUENOS AIRES

    lead OTHER

Principal Investigators

  • GLENDA ERNST · HOSPITAL BRITANICO DE BUENOS AIRES

  • JHON AVILA · HOSPITAL BRITANICO DE BUENOS AIRES

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-03
Primary Completion
2021-08-28
Completion
2022-02-02

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04754841 on ClinicalTrials.gov